Oramed Pharmaceuticals Inc. (ORMP) Stock Price

ORMPStock

$5.21+125.23%52W

Market Cap$216.72M

P/E2.84x

PEG Ratio—

Div yield0.00%

Beta1.26

ORMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)34.81%

Price vs S&P 500 (4W)12.54%

VGM Score55.17

P/E Ratio (Annual)2.84x

Indicated Dividend Yield (Annual)0.00%

Book Value / Share (Quarterly)$5.82

P/TBV (Annual)0.58x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-9.52%

Cash Flow / Share (Quarterly)$-0.21

Price vs S&P 500 (YTD)57.16%

Gross Margin (TTM)0.65%

Net Profit Margin (TTM)-838.40%

EPS (TTM)$2.59

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$2.59

Revenue Growth (5Y)-5.83%

EPS (Annual)$1.51

ROI (Annual)32.07%

Gross Margin (Annual)0.65%

Net Profit Margin (5Y Avg)29.27%

Cash / Share (Quarterly)$1.61

P/E Basic Excl Extra (TTM)1.66x

P/E Normalized (Annual)2.84x

ROA (Last FY)27.74%

Revenue Growth TTM (YoY)-30.93%

EBITD / Share (TTM)$-0.34

ROE (5Y Avg)-1.74%

Operating Margin (TTM)-1070.36%

Cash Flow / Share (Annual)$-0.23

P/B Ratio0.76x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$4,926,900

EV / Revenue (TTM)58.67x

Net Interest Coverage (TTM)-2.84x

ROA (TTM)49.75%

EV / EBITDA (TTM)1.25x

EPS Incl Extra (Annual)$1.51

Current Ratio (Annual)6.98x

Quick Ratio (Quarterly)6.23x

3-Month Avg Trading Volume0.26M

52-Week Price Return125.23%

P/E Incl Extra (TTM)1.66x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.70

P/S Ratio (Annual)135.97x

Asset Turnover (Annual)0.01x

52-Week High$5.19

Operating Margin (5Y Avg)-1139.09%

EPS Excl Extra (Annual)$1.51

CapEx CAGR (5Y)-52.70%

26-Week Price Return46.06%

Quick Ratio (Annual)6.84x

13-Week Price Return10.05%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.45x

Enterprise Value$182.20M

Revenue / Share Growth (5Y)-13.06%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)9.17%

Revenue / Employee (Annual)$103,100

Pretax Margin (Annual)379.70%

Cash / Share (Annual)$3.21

3-Month Return Std Dev57.28%

Gross Margin (5Y Avg)78.65%

Net Income / Employee (TTM)$8,439,500

ROE (Last FY)32.07%

Net Interest Coverage (Annual)-0.46x

EPS Basic Excl Extra (Annual)$1.51

P/FCF (TTM)78.66x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.59

ROI (TTM)55.11%

P/S Ratio (TTM)43.31x

Pretax Margin (5Y Avg)108.79%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$3.84

Forward P/E2.19x

Price vs S&P 500 (52W)106.92%

P/E Ratio (TTM)1.66x

EPS Growth TTM (YoY)60.34%

Year-to-Date Return69.12%

5-Day Price Return0.84%

EPS Normalized (Annual)$1.51

ROA (5Y Avg)-2.24%

Net Profit Margin (Annual)412.31%

Month-to-Date Return18.43%

Cash Flow / Share (TTM)$-0.42

EBITD / Share (Annual)$-0.35

Operating Margin (Annual)-1176.79%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-1.90%

P/E Excl Extra (TTM)1.66x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$2.59

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)0.57x

Pretax Margin (TTM)-838.40%

Book Value / Share (Annual)$5.09

Price vs S&P 500 (13W)7.25%

Beta1.26x

P/FCF (Annual)35.12x

Revenue / Share (TTM)$0.00

ROE (TTM)55.11%

52-Week Low$2.06

vGradeC

gGradeD

mGradeB

vgmGradeC

ORMP Earnings Surprise History

Q2 250.31est. -0.04

Q3 251.13est. -0.04

Q4 250.25est. 0.00

Q1 260.91est. —

Q2 261.84est. 0.43

ORMP Analyst Recommendations

Mar 2025

Apr 2025

May 2025

Jun 2025

2.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ORMPOramed Pharmaceuticals Inc.	C	D	B	$5.21
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals develops proprietary oral delivery technology for therapeutic proteins, including insulin, designed to survive the stomach's harsh environment. The platform enables injectable biologics to be administered as oral medications, potentially improving patient convenience and compliance. Its clinical pipeline includes ORMD-0801 for diabetes and ORMD-0901.